Current Report Filing (8-k)
October 02 2018 - 5:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 2018
ENDOLOGIX, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-28440
|
|
68-0328265
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
2 Musick, Irvine, CA
|
|
92618
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (949)
595-7200
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 Regulation FD Disclosure.
On October 2, 2018, Endologix, Inc. (the Company) issued a press release announcing preliminary unaudited revenue results for the quarter
ended September 30, 2018 and updated revenue guidance for the fiscal year ended December 31, 2018. The press release also announced that the Company is hosting a meeting for financial analysts and investment professionals in New York, New
York on October 2, 2018 at 4:15 P.M. Eastern Time (the Investor Meeting). A copy of the press release is attached hereto as Exhibit 99.1.
The
slides accompanying the Companys presentation at the Investor Meeting are available on the Investors section of the Companys website at www.endologix.com. In addition, a replay of the presentation will be available on the
same website after the Investor Meeting.
Certain statements made in the presentation are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. The Company cautions that these forward-looking statements are based on managements current expectations, estimates, forecasts and projections about the Company, and assumptions management
believes are reasonable, and are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. See the Safe Harbor disclaimer in the presentation for
additional information.
The information set forth in this Item 7.01, including Exhibit 99.1 attached hereto, is deemed to be furnished and
shall not be deemed to be filed for purposes of the Securities Exchange Act of 1934, as amended (the Exchange Act), and shall not be incorporated by reference into any registration statement or other document filed under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
ENDOLOGIX, INC.
|
|
|
|
|
Date: October 2, 2018
|
|
|
|
|
|
/s/ Vaseem Mahboob
|
|
|
|
|
|
|
Vaseem Mahboob
|
|
|
|
|
|
|
Chief Financial Officer
|
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2023 to Sep 2024